血浆DAPK基因启动子甲基化与非小细胞肺癌的关系

RELATIONSHIP BETWEEN NON-SMALL CELL LUNG CANCER AND PLASMA DAPK GENE METHYLATION

目的探讨死亡相关蛋白激酶(DAPK)启动子甲基化在非小细胞肺癌病人中的表达及其临床意义。方法采用甲基化特异性PCR的方法,对42例健康人和61例非小细胞肺癌病人外周血中DAPK基因启动子甲基化的情况进行检测。结果在42例健康人的血浆中均未检出DAPK基因的甲基化,而61例非小细胞肺癌病人中,18例检测到DAPK基因启动子甲基化(χ2=15.018,P<0.05)。DAPK基因启动子甲基化与非小细胞肺癌病人性别、肿瘤分化程度无关,但与病人淋巴结转移和临床分期有关(χ2=4.961、9.678,P<0.05)。结论 DAPK基因启动子甲基化与非小细胞肺癌的淋巴结转移和临床分期有相关性,有可能作为评估非小细胞肺癌分期的分子生物学指标。

Objective To investigate the expression of death-associated protein kinase （DAPK） promoter methylation in non-small cell lung cancer （NSCLC） patients and its clinical significance. Methods Using methylation specific gene amplification （MSPCR） method, the methylation of DAPK promoter of peripheral blood in 42 healthy individuals and 61 NSCLC patients was detected. Results In 42 healthy individuals, no plasma DAPK gene methylation was detected, and in the 61 NSCLC patients, 18 were found to be positive （x^2=15. 018,P〈0.05）. DAPK gene promoter methylation in NSCLC patients was not associated with the sex and the degree of tumor differentiation, but related with lymph node metastasis and clinical staging （x^2= 4.96l, 9.678;P% 0.05）. Conclusion DAPK gene promoter methylation is correlated with lymph node metastasis and clinical stage of NSCLC, which may be used as a molecular biological parameter for staging of this malignancy.